Triplet Therapy Including Belamaf Prolongs Survival in Multiple Myeloma
Triplet therapy of belantamab mafodotin, bortezomib, dexamethasone beneficial for relapsing or refractory multiple myeloma.
Triplet therapy of belantamab mafodotin, bortezomib, dexamethasone beneficial for relapsing or refractory multiple myeloma.
Approximately 31,000 people are living with amyotrophic lateral sclerosis (ALS) in the United States, with an average of 5,000 new cases every year, according to…
Researchers successfully used a brain-computer interface to synthesize speech directly from brain activity in an ALS patient, achieving 80% word recognition accuracy by listeners, showcasing…
The FDA would only withdraw a rare disease gene therapy for “pretty clear” reasons, such as when there is minimal benefit with extensive side effects.…
No association seen for mAb during breastfeeding with infant hospitalization, systemic antibiotic use, developmental delay.
This very special event will celebrate NORD’s legacy and achievements, and honor those individuals and organizations doing remarkable work on behalf of the rare disease…
After Orchard Therapeutics’ gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert…
Please join Rep. Quigley and the ALS Caucus Co-Chairs, Reps. Calvert, Crow, Fitzpatrick, and Sewell, for an event highlighting research and care for ALS. ALS…
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Judith Luker discusses the sudden unexpected death in epilepsy communication gap and the importance of physician-patient conversations.
Ponni Subbiah, MD, MPH, Senior Vice President Global Head of Medical Affairs and Chief Medical Officer, Acadia Pharmaceuticals, discusses trofinetide for the treatment of Rett…